Thank you, Abbey, morning, good and everyone.
advance Gamida to prioritize resources across have patients efforts organization Omisirge's execute Cell access to could launch ensure and continues to Omisirge. need in the and
launch to pleased is a that great are the off share We to start.
from at with centers. with both launch insights sources their transplanters multidisciplinary the our and pre- existing terms needs both real-world consistent of donor and teams experience Omisirge market unmet in Our is in post-approval interest and
total by which of providers blinded at the XX% you peak, approval. five showed As healthcare Cell could with has payers, XXXX. market Omisirge recall, to a market That independent pre and occur may conducted studies both capture and approximately post estimate Gamida share we insight potential
patients those that other eligible Omisirge using for as and were capture consistent of each Omisirge market could X,XXX not The an for from find appropriate as year insights transplant sources are could using well approximately transplanters instead donor. come the share for transplanters donor who Omisirge
we data show donor. Although likely patients independent each appropriate this cannot who more about an about find now we number previously X,XXX, is have year it X,XXX be estimated to that
only reminder, a patient treatment be goes transplant As remaining to with may that hematologic their potential option. a malignancy since a
not a disease. most approximately to those who X,XXX patients succumb could they For will find donor, their likely
X about at have the trial. very passionate Omisirge option have Omisirge in approval, sure are Phase and patients. few transplant months since of centers potential we interest not from in to centers, Today seen Gamida their were strong access the including centers transplant as that a for We part making past
onboarded, and this centers process. additional been Jefferson eight actively Center, are UCLA University As Philadelphia, Health in have the Ohio Medical Health. XX of in morning, such as transplant including centers onboarding centers Duke the transplant And State
XX% We are which about the of in of top engaged with transplant the conduct virtually XX all the centers, U.S.
number the excited the by exceeded end XX centers centers possibly Gamida of boarded goal onboarding of expectations on transplant and with regard to our very remains to we to am our Cell say XXXX track of have exceed to that I that on date. to XX
transplant center source. as training procedures quickly onboarding the works transplant center using center. personnel with team each the a on center required How is policies of a to donor transplant closely and Our transplant administrative Omisirge clinical is needs individual onboarded determined by and begin
and staff onboarding under good This research. patients who the to can from the in include like status candidates of availability be factors participate may currently evaluation
Our individual team is and time to and nimble transplant lines meet needs. onboarding center customizes patient
and needed policies sources consistent and are, personnel. with transplant Omisirge approach procedures and clinical to other familiar donor therefore, are center for very The
the than for cell typically completed very quickly ultimately, process So onboarding therapies. more be can quickly, other
on ensuring Omisirge. also for been coverage focused have We payer
coverage the U.S. patients in We have the vast for majority confirmed of
of national than we additional in discussions In out payers. to XX% coverage. of coverage with confirmed fact, This includes commercial lives with top And nine expand further are more have coverage. ongoing payers the commercial XX
we Medicare. and for June, also secured now patients reimbursement we that confirmed year, in we by codes ICD-XX Last have our CMS Omisirge-specific coverage covered and announced
our We Department Veteran have in are know for Medicaid, for required working it also We of the and clinical time transplant. takes Defense and the all them to transplant under Affairs. Department that in evaluate patients from patients trials the get who and ready place documentation covered of
procedures. transplant preparing approach center This by each is and patient true center's on can for transplant for for all line and time the a donor based vary specific sources and policies enrolled excited providers patients healthcare ensure was am have which in personalized to patients Gamida experience. the created that share positive a to access therapy Cell's I are program, and can and
patient centers benefit the The including date donor programs and Assist Cell of with assistance. verification, in Assist, is assistance, patients it Omisirge also work a select can When terms patient Gamida they their and their that transplant This or coinsurance support patient significant to in patient for transplant manufacturing journey step and a Cell patient's to transplantation. enrolls physician schedule use Omisirge the Assist, signals co-pay for intend Cell enroll to source. as Gamida Gamida a
Cell, Once manufacturing. donor is received Gamida the unit by begin we ready blood the source and selected Omisirge by cord to transplanter is are patient's the
been clinical over a batches As we successfully for facilities reminder, year. have in a manufacturing our
and reliably We of to have are XX place, start ready the within we an experienced from team in deliver days manufacturing. Omisirge
rapid the centers. launch appropriate hire to and the two seeing MSLs. feel plans this current regional of support have four capitalize continue liaisons interest managers To expansion commercial four and We we is account support additional we medical demand momentum the science our four Omisirge, for and of an on to team transplant directors to are account from investment the and
address transplantation. unmet to cell a mission element back curative Gamida mission, critical on cancers. Omisirge potential with was delivering and and blood therapies that based for deliver built increase on is Cell stem to Going needs potentially its patients access our to core in
every launch, gratifying patients' supportive interest of have market transplant centers impact The and from the possible are enthusiasm support this knowing can Omisirge both insights. are We lives. the potentially meaningful resource prioritizing to on prelaunch and
access Our Omisirge. working patient been of transplant stem in Cell Gamida transplant need that has cell to a team ensure hard demand at center every and has meet to
I'd like and Chief call over Medical Simantov, to to Ronit With Scientific Officer. that, Chief our Ronit? the turn
